

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P. J. Towers Dalal Street <u>Mumbai-400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai-400 051</u>
Code: <b>532321</b>	Symbol: <b>CADILAHC</b>
<b>Date:</b> April 16, 2020	
<b>Sub.:</b> Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015	

Dear Sir / Madam,

With reference to the captioned subject, we would like to inform that the Board of Directors at its meeting held today, has approved and signed the Definitive Agreement for sale of 9,44,233 equity shares of Rs. 10/- each fully paid-up, representing 2% of the total paid-up share capital of Windlas Healthcare Private Limited ("WHPL"), a subsidiary company to Windlas Biotech Private Limited ("WBPL").

Upon completion of the transaction in relation to the sale of the said equity shares, the total shareholding of the Company in WHPL will reduce to 49.00% (forty-nine percent) from 51.00% (fifty-one percent) and WHPL will cease to be the subsidiary of the Company.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, for sale or disposal of unit(s) or division(s) or subsidiary of the listed entity are provided at Annexure-"A".

Please take the above information on record.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



Enc.: As above

Annexure-“A”


Sr. No.	Particulars	Response
1.	the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	9,44,233 equity shares, representing 2% of the total equity share capital of Windlas Healthcare Private Limited (“WHPL”), a subsidiary of Cadila Healthcare Limited (“CHL”), are proposed to be sold to Windlas Biotech Private Limited (“WBPL”).  Turnover of WHPL for the year ended on March 31, 2019* was Rs. 22.4 crores, out of which turnover of Rs. 6.1 crores was included in the consolidated turnover, representing 0.05% of the turnover of the Company on a consolidated basis.  Net worth of WHPL for the year ended on March 31, 2019* was Rs. 206.4 crores.
2.	date on which the agreement for sale has been entered into	Definitive Agreement for the purpose was entered into on April 16, 2020.
3.	the expected date of completion of sale/disposal	The transaction is expected to be completed within 30 (Thirty) business days.
4.	Consideration received from such sale/disposal	Rs. 4,05,92,577/- (Rupees Four Crores Five Lakh Ninety Two Thousand Five Hundred and Seventy Seven only) will be received.
5.	brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof.	WBPL is the promoter company of WHPL. WBPL does not belong to CHL’s promoter group.  WBPL is engaged in the business of pharmaceuticals.
6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”	The transaction will not fall under related party transactions.



Sr. No.	Particulars	Response
7.	additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

\* As the audited financial statements for the year ended on March 31, 2020 are yet not prepared, the figures are provided for the year ended on March 31, 2019.

For, CADILA HEALTHCARE LIMITED

  
DHAVAL N. SONI  
COMPANY SECRETARY

